Article

Glucagon-Like Peptide-1 Receptor Agonists: A New Frontier in Treating Alcohol Use Disorder

2025-05-23

Abstract excerpt

<h4>Background: </h4> /Objectives: Glucagon-like peptide-1 receptor agonists (GLP-1RAs), which were originally developed for managing type 2 diabetes by enhancing insulin secretion and reducing appetite, have emerged as promising candidates in alcohol use disorder (AUD). These medications offer a dual mechanism of action that aligns with the multifaceted nature of addiction by targeting both peripheral metabolic a...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 269b7481-5f01-5330-9d56-a0921f9caf4d
DOI: 10.20944/preprints202505.1789.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Glucagon-Like Peptide-1 Receptor Agonists: A New Frontier in Treating Alcohol Use DisorderDOI 10.20944/preprints202505.1789.v1Read

Crosstalk between alcohol use disorder and obesity: two sides of the same coin?Semantic proximity Read

The glucagon-like peptide-1 receptor as a potential treatment target in alcohol use disorder: evidence from human genetic association studies and a mouse model of alcohol dependence.Semantic proximity Read

A Brain Reward Circuit Inhibited By Next-Generation Weight Loss DrugsSemantic proximity Read

Progress in mind: focus on alcohol use disorders, an elsevier resource centre.Semantic proximity Read

Current Pharmacotherapies for Alcohol Use Disorder in Italy: From Neurobiological Targets to Clinical PracticeSemantic proximity Read

Exploring the off-Label use of liraglutide in the treatment of obesity: a reviewSemantic proximity Read

The Role of Ghrelin/GHS-R1A Signaling in Nonalcohol Drug Addictions.Semantic proximity Read

Highway to the danger zone? A cautionary account that GLP-1 receptor agonists may be too effective for unmonitored weight lossSemantic proximity Read

In Silico Pharmacogenomic Assessment of Glucagon-like Peptide-1 (GLP1) Agonists and the Genetic Addiction Risk Score (GARS) Related Pathways: Implications for Suicidal Ideation and Substance Use DisorderSemantic proximity Read

Assessing Holistic Health Interventions and Approaches for Individuals with Alcohol Use Disorder (AUD): Protocol for a Scoping ReviewSemantic proximity Read

Naltrexone for the treatment of alcoholism: clinical findings, mechanisms of action, and pharmacogenetics.Semantic proximity Read

The FDA-approved drug apremilast suppresses alcohol intake: clinical and pre-clinical validationSemantic proximity Read